erenumab
Treatment for Cluster Headache
Erenumab is a monoclonal antibody that selectively targets the calcitonin gene-related peptide (CGRP) receptor, blocking CGRP's neurogenic inflammatory actions. By inhibiting CGRP signaling, it reduces neurogenic inflammation and pain transmission, potentially decreasing the frequency and severity of cluster headache episodes. While primarily studied and approved for migraine prevention, emerging research suggests it may have therapeutic potential in cluster headache management.
1083
REPORTED SIDE EFFECTS